Table 3.
Serum visfatin concentration and visfatin mRNA hepatic expression in CHC patients according to liver histology
| Histopathological results | Number of patients (%) | Serum visfatin [ng/ml] | p | Liver visfatin/GAPDH | p | |
|---|---|---|---|---|---|---|
| Necro-inflammatory activity grade | 1 | 12 (18.8%) | 23.75 ±4.99 | NS | 0.93 ±0.42 | NS |
| 2 | 35 (55.1%) | 21.91 ±5.00 | 1.17 ±0.57 | |||
| 3-4 | 16 (26.1%) | 24.46 ±7.33 | 1.31 ±0.76 | |||
| Fibrosis stage | 1 | 26 (42.0%) | 22.73 ±4.40 | NS | 1.20 ±0.63 | NS |
| 2 | 26 (42.0%) | 22.57 ±6.96 | 1.10 ±0.53 | |||
| 3-4 | 11 (15.9%) | 24.39 ±5.50 | 1.24 ±0.75 | |||
| Steatosis presence | present | 31 (49.3) | 21.87 ±5.31 | NS | 1.35 ±0.75 | 0.009 |
| absent | 32 (50.7%) | 23.95 ±6.00 | 0.98 ±0.34 | |||
| Hepatocyte ballooning grade | 0-1 | 24 (38.4%) | 23.18 ±5.32 | NS | 1.20 ±0.50 | NS |
| 2 | 39 (61.6%) | 22.92 ±6.64 | 1.13 ±0.68 | |||